

INVITED EDITORIAL

Toward an Understanding of the Cause of Mitral Valve Prolapse

Jeffrey A. Towbin

Departments of Pediatrics (Cardiology), Molecular and Human Genetics, and Cardiovascular Sciences, Texas Children's Hospital Foundation Chair in Pediatric Cardiac Research, Texas Children's Hospital, Baylor College of Medicine, Houston

Mitral valve prolapse (MVP [MIM 147700]) is among the most common cardiovascular abnormalities, affecting ~2%–8% of the population (Levy and Savage 1987). In fact, this abnormality is believed to affect as many as 15%–20% of young women and a significantly lower proportion (1%–3%) of men, suggesting to some clinicians that this abnormality is, in most cases, a trivial variant of normal valve architecture. However, since some adult patients ultimately require mitral valve replacement (Carpentier et al. 1980; Alpert et al. 1998) and since MVP is commonly associated with well-known clinical entities such as Marfan syndrome and Ehlers-Danlos syndrome (Glesby and Pyeritz 1989), others believe MVP to be a form of significant heart disease (Boudarias 1991).

MVP is described as excessive mitral valve tissue that leads to billowing of the mitral valve leaflets, with or without prolapse and mitral regurgitation (MR) (Frable 1969; Kern and Tucker 1972; Barlow and Pocock 1979; Virmani et al. 1987). Clinically, the diagnosis is suspected when a mid-systolic click and/or late-systolic cardiac murmur are auscultated (Barlow et al. 1963; Barlow and Pocock 1979; Perloff et al. 1986). The diagnosis is confirmed by echocardiography (Nishimura et al. 1985; Levine et al. 1988), and occasionally there is disparity in the physical exam findings and echocardiographic findings (Weiss et al. 1975). In some families, several affected individuals can be identified, with inheritance usually being autosomal dominant (Shappell et al. 1973; Weiss et al. 1975; Bareiss 1976; Cooper and Abinader 1981; Strahan et al. 1983). Age dependence and sex dependence (Devereux et al. 1982) also have been noted. In addition, X-linked inheritance has been reported in a forme fruste of MVP, called "severe myxomatous valvular dystrophy," which has been mapped to Xq28

(Kyndt et al. 1998). In families with MVP, clinical heterogeneity is quite significant, with severely abnormal valves noted in some and with nearly normal valves seen in other members of the same family (Zuppiroli et al. 1998). In addition, most patients are asymptomatic, although a portion of the affected individuals have severe symptoms of congestive heart failure with severe MR. Some individuals (usually teenage girls) have a personality type that includes a high-strung style, and these individuals commonly complain of palpitations, chest pain, and dizziness (which is due to hyperventilation).

In this issue of the *Journal*, Disse et al. (1999) localize the first locus for autosomal dominant myxomatous MVP (MMVP) to chromosome 16p11.2-p12.1. This work highlights a number of important points. First, the authors have avoided issues of uncertain diagnosis, by selecting severely affected index cases in whom mitral valve-replacement surgery was required. In addition, only first-degree relatives were recruited for evaluation, and each relative underwent double-blind echocardiographic analysis, thus allowing for consistent diagnostic criteria. This approach also enabled the authors to maximally diagnose family members, avoiding the insensitivity noted when only family history is used. This point previously had been highlighted by Michels et al. (1985, 1992), who showed that the use of family history alone identified 6% of relatives of probands as having dilated cardiomyopathy (DCM), whereas echocardiograms performed on all family members irrespective of history identified 20% of these members as being affected, albeit asymptomatic in most cases.

Another important finding by Disse et al. is that, in the families studied, equal numbers of men and women were affected (i.e., there were no sex-dependent differences), a finding that differs from the female predominance reported by others. Whether clinical signs, symptoms, and outcomes differ between the sexes was not studied by Disse et al., however.

Because of the large distance of the MMVP1 critical region, which now is considered to be in the 5–34-cM range, a positional candidate-gene approach has been used by Disse et al., which requires a detailed understanding of the clinical and histopathological phenotype. As these authors note, genes involved in the structure

Received September 14, 1999; accepted for publication September 16, 1999; electronically published October 5, 1999.

Address for correspondence and reprints: Dr. Jeffrey A. Towbin, Pediatric Cardiology, Baylor College of Medicine, One Baylor Plaza, Room 333E, Houston, TX 77030-3498. E-mail: jtowbin@bcm.tmc.edu

This article represents the opinion of the author and has not been peer reviewed.

© 1999 by The American Society of Human Genetics. All rights reserved.
0002-9297/1999/6505-0005\$02.00

or development of the atrioventricular valves are obvious possibilities. Other reasonable choices are needed, however. Hints with regard to candidate-gene selection could come from successful studies of other cardiovascular disorders. My colleagues and I recently have described the "final common pathway" hypothesis of cardiovascular disease, which suggests that hereditary cardiovascular diseases with similar phenotypes and genetic heterogeneity occur because of abnormalities of genes encoding proteins either with similar functions or participating in a common pathway cascade (Towbin 1999; Towbin et al. 1999). For instance, all of the genes responsible for hypertrophic cardiomyopathy (HCM)—a cardiac disorder in which thickening of both the left ventricle and interventricular septum occurs in association with diastolic dysfunction, hypercontractile systolic function, and myofiber disarray (Maron 1997)—encode proteins composing the sarcomere (i.e., contractile units of the heart) (Thierfelder et al. 1994). In addition, all of the genes responsible for inherited forms of ventricular arrhythmias (as in the long QT syndromes and Brugada syndrome) are due to mutations in cardiac ion channels (Wang et al. 1998; Chen et al. 1998). Recently, I have suggested that abnormalities of cytoskeletal proteins will underlie the development of dilated cardiomyopathy (DCM) and that, since the sarcomere and cytoskeleton are connected via dystrophin and the actin cytoskeleton, intermediate phenotypes are likely (Towbin 1998). The identification of mutations in actin that are near the dystrophin-binding site and that cause DCM (Olson et al. 1998) and of mutations at the sarcomeric end that cause HCM (Mogensen et al. 1999) further support this hypothesis.

Taking advantage of the final common pathway hypothesis, one could evaluate previously identified genetic mutations in patients with MVP associated with other diseases. For years there has been speculation that connective-tissue abnormalities cause MVP (Glesby and Pyeritz 1989; Henney et al. 1989; Tamura et al. 1995). This speculation has been supported by a variety of studies. The fibrillin-1 gene, when mutated, causes Marfan syndrome in which MVP and aortic-root dissection are common (Glesby and Pyeritz 1989). This connective tissue-encoding gene gives rise to a wide variety of clinical phenotypes when mutated, including classic Marfan syndrome (Lee et al. 1991; Towbin and Roberts 1998), with its pleiotropic findings that include cardiac, vascular, bone/skeletal, and ocular abnormalities, to pure skeletal abnormalities, to pure cardiovascular phenotypes (i.e., aortic aneurysm) (Putnam et al. 1995; Sood et al. 1996; Furthmayr and Francke 1997). Another cardiovascular disorder associated with connective-tissue abnormalities is Williams syndrome (Williams et al. 1961; Beuren 1972; Ewart et al. 1993; Morris 1998), which is associated with mental retardation, dysmorphisms, and su-

pravalvar aortic stenosis associated with elastin mutations. Mutations in this same gene also cause a pure cardiovascular disorder known as "familial supravalvar aortic stenosis" (Eisenbert et al. 1964; Ewart et al. 1994; Furthmayr and Francke 1997; Morris 1998). Finally, Ehlers-Danlos syndrome, with its abnormalities of the aorta and mitral valve that are associated with skeletal abnormalities (Tsipouras et al. 1986; DePaepe et al. 1997; Michalickova et al. 1998) and osteogenesis imperfecta, has associated skeletal and vascular abnormalities that are due to mutations in collagen genes (Willing et al. 1994). Thus, the common final pathway involved in aortic and mitral valve abnormalities associated with connective-tissue disorders appears to be genes encoding connective-tissue proteins. Therefore, it seems reasonable to suggest that pure MMVP could arise from abnormalities of genes encoding either members of this family of proteins or products that interact in the cascade of these connective-tissue functions. As the genes for this genetically heterogeneous disorder are identified, the utility of this common-pathway concept will become either apparent or discredited. In either case, knowledge of the affected genes should allow for a better understanding of the clinical spectrum and potentially should allow for improved clinical care of affected patients. The study by Disse and colleagues is an excellent first step.

Electronic-Database Information

Accession numbers and URL for data in this article are as follows:

Online Mendelian Inheritance in Man (OMIM), <http://www.ncbi.nlm.nih.gov/Omim> (for MVP [MIM 147700])

References

- Albert JS, Sabik J, Cosgrove DM (1998) Mitral valve disease. In: Topol EJ (ed) Textbook of cardiovascular medicine. Lippincott-Raven, Philadelphia, pp 519–528
- Bareiss P (1976) Familial forms of the mid-end systolic click and murmur syndrome with deviations of left ventricular kinetics. *Arch Mal Coeur Vaiss* 69:71–81
- Barlow JB, Pocock WA (1979) Mitral valve prolapse, the specific billowing mitral leaflet syndrome, or an insignificant non-ejection systolic click. *Am Heart J* 97:277–285
- Barlow JB, Pocock WA, Marchand P, Denny M (1963) The significance of late systolic murmur. *Am Heart J* 66:443–452
- Beuren AJ (1972) Supravalvular aortic stenosis: a complex syndrome with and without mental retardation. *Birth Defects* 8:45–56
- Boudarias JP (1991) Mitral valve prolapse: a severe abnormality? *Arch Mal Coeur Vaiss* 84:981–986
- Carpentier A, Chauvaud S, Fabiani JN, Deloche A, Relland J, Lessana A, D'Allaines C, et al (1980) Reconstructive surgery of mitral valve incompetence: ten-year appraisal. *J Thorac Cardiovasc Surg* 79:338–348

- Chen Q, Kirsch GE, Zhang D, Brugada R, Brugada R, Brugada P, Potenza D, et al (1998) Genetic basis and molecular mechanism for ventricular fibrillation. *Nature* 392:293-296
- Cooper MJ, Abinader EG (1981) Family history in assessing the risk for progression mitral valve prolapse: report of a kindred. *Am J Dis Child* 135:647-649
- DePaepe A, Nuytinck L, Hausser I, Anton-Lamprecht I, Naeuyaert J-M (1997) Mutations in the COL5A1 gene are causal in the Ehlers-Danlos syndromes I and II. *Am J Hum Genet* 60:547-554
- Devereux RB, Brown WT, Kramer-Fox R, Sachs I (1982) Inheritance of mitral valve prolapse: effect of age and sex on gene expression. *Ann Intern Med* 97:826-832
- Disse S, Abergel E, Berrebi A, Houot A-M, LeHenzey J-Y, Diebold B, Guize L, et al (1999) Mapping of a first locus for autosomal dominant myxomatous mitral valve prolapse to chromosome 16p11.2q-p12.1. *Am J Hum Genet* 65:1242-1251 (in this issue)
- Eisenbert R, Young D, Jacobson B, Boito A (1964) Familial supravalvular aortic stenosis. *Am J Dis Child* 108:341-347
- Ewart AK, Jin W, Atkinson D, Morris CM, Keating MT (1994) Supravalvular aortic stenosis associated with a deletion disrupting the elastin gene. *J Clin Invest* 93:1071-1077
- Ewart AK, Morris CA, Atkinson D, Jin W, Sternes K, Spallone P, Stock AD, et al (1993) Hemizygosy at the elastin locus in a developmental disorder, Williams syndrome. *Nat Genet* 5:11-16
- Frale WJ (1969) Mucinous degeneration of the cardiac valves: the "floppy valve" syndrome. *J Thorac Cardiovasc Surg* 58:62-70
- Furthmayr H, Francke U (1997) Ascending aortic aneurysm with or without features of Marfan syndrome and other fibrillinopathies: new insights. *Semin Thorac Cardiovasc Surg* 9:191-205
- Glesby MJ, Pyeritz RE (1989) Association of mitral valve prolapse and systemic abnormalities of connective tissue: a phenotypic continuum. *JAMA* 262:523-528
- Henney AM, Tsiouras P, Schwartz RC, Child AH, Devereux RB, Leach GJ (1989) Genetic evidence that mutations in the COL1A1, COL1A2, COL3A1, or COL5A2 collagen genes are not responsible for mitral valve prolapse. *Br Heart J* 61:292-299
- Kern WH, Tucker BL (1972) Myxoid changes in cardiac valves: pathologic, clinical and ultrastructural studies. *Am Heart J* 84:294-301
- Kyndt F, Schott JJ, Trochu JN, Baranger F, Herbert O, Scott V, Fressinaud E, et al (1998) Mapping of X-linked myxomatous valvular dystrophy to chromosome Xq28. *Am J Hum Genet* 62:627-632
- Lee B, Godfrey M, Vitale E, Hori H, Mattei MG, Sarfarazi M, Tsiouras P, et al (1991) Linkage of Marfan syndrome and a phenotypically related disorder to two different fibrillin genes. *Nature* 352:330-334
- Levine RA, Stathosgiannis E, Newell JB, Harrigan P, Weyman AE (1988) Reconsideration of echocardiographic standards for mitral valve prolapse: lack of association between leaflet displacement isolated to the apical four chamber view and independent echocardiographic evidence of abnormality. *J Am Coll Cardiol* 11:1010-1019
- Levy D, Savage D (1987) Prevalence and clinical features of mitral valve prolapse. *Am Heart J* 113:281-290
- Maron BJ (1997) Hypertrophic cardiomyopathy. *Lancet* 350:127-133
- Michalickova K, Susic M, Willing MC, Wenstrup RJ, Cole WG (1998) Mutations of the $\alpha 2$ (V) chain of type V collagen impair matrix assembly and produce Ehlers-Danlos syndrome type I. *Hum Mol Genet* 7:249-255
- Michels VV, Driscoll DJ, Miller FA Jr (1985) Familial aggregation of idiopathic dilated cardiomyopathy. *Am J Cardiol* 55:1232-1233
- Michels VV, Moll PP, Miller FA, Tajik AJ, Chu JS, Driscoll DJ, Burnett JC, et al (1992) The frequency of familial dilated cardiomyopathy in a series of patients with idiopathic dilated cardiomyopathy. *N Engl J Med* 326:77-82
- Mogensen J, Klausen IC, Pedersen AK, Egeblad H, Bross P, Kruse TA, Gregersen N, et al (1999) α -Cardiac actin is a novel disease gene in familial hypertrophic cardiomyopathy. *J Clin Invest* 103:R39-R43
- Morris CA (1998) Genetic aspects of supravalvular aortic stenosis. *Curr Opin Cardiol* 13:214-219
- Nishimura RA, McGoon MD, Shub C, Miller FA Jr, Ilstrup DM, Tajik AJ (1985) Echocardiographically documented mitral valve prolapse. *N Engl J Med* 313:1305-1309
- Olson TM, Michels VV, Thibodeau SN, Tai YS, Keating MT (1998) Actin mutation in dilated cardiomyopathy, a heritable form of heart failure. *Science* 280:750-752
- Perloff JK, Child JS, Edwards JS, Edwards JE (1986) New guidelines for the clinical diagnosis of mitral valve prolapse. *Am J Cardiol* 57:1124-1129
- Putnam EA, Zhang H, Ramirez F, Milewicz DM (1995) Fibrillin-2 (FBN2) mutations result in the Marfan-like disorder, congenital contractural arachnodactyly. *Nat Genet* 11:456-458
- Shappell SD, Marshall CE, Brown RE, Bruce TA (1973) Sudden death and the familial occurrence of mid-systolic click, late systolic murmur syndrome. *Circulation* 48:1128-1134
- Sood SR, Eldadah ZA, Krause WL, McIntosh I, Dietz HC (1996) Mutation in fibrillin-1 and the marfanoid-craniosynostosis (Shprintzen-Goldberg) syndrome. *Nat Genet* 12:209-211
- Strahan NV, Murphy EA, Fortuin NJ, Come PC, Humphries JO (1983) Inheritance of the mitral valve prolapse syndrome: discussion on a three dimensional penetrance model. *Am J Med* 74:967-972
- Tamura K, Fukunda Y, Ishizaki M, Masuda Y, Yamanaka N, Ferrans VJ (1995) Abnormalities in elastic fibers and other connective-tissue components of floppy mitral valve. *Am Heart J* 129:1149-1158
- Thierfelder L, Watkins H, MacRae C, Lamas R, McKenna W, Vosberg HP, Seidman JG, et al (1994) α -Tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: a disease of the sarcomere. *Cell* 77:701-712
- Towbin JA (1998) The role of cytoskeletal proteins in cardiomyopathies. *Curr Opin Cell Biol* 10:131-139
- Towbin JA, Bowles KR, Bowles NE (1999) Etiologies of cardiomyopathy and heart failure. *Nat Med* 5:266-267
- Towbin JA, Roberts R (1998) Cardiovascular diseases due to

- genetic abnormalities. In: Schlant RC, Alexander RW (eds) *Hurst's the heart*. McGraw-Hill, New York, pp 1877–1924
- Tsipouras P, Byers PH, Schwartz RC, Chu ML, Weil D, Pepe G, Cassidy SB, et al (1986) Ehlers-Danlos syndrome type IV: cosegregation of the phenotype to a COL3A1 allele of type III procollagen. *Hum Genet* 74:41–46
- Virmani R, Atkinson JB, Forman MB, Robinowitz M (1987) Mitral valve prolapse. *Hum Pathol* 18:596–602
- Wang Q, Bowles NE, Towbin JA (1998) The molecular basis of long QT syndrome and prospects for therapy. *Mol Med Today* 4:382–388
- Weiss AN, Mimbs JW, Ludbrook PA, Sobel BE (1975) Echocardiographic detection of mitral valve prolapse, exclusion of false positive diagnosis and determination of inheritance. *Circulation* 52:1091–1096
- Williams JCP, Barratt-Boyers BG, Lowe JB (1961) Supravalvular aortic stenosis. *Circulation* 24:1311–1318
- Willing MC, Deschenes SP, Scott DA, Byers PH, Slayton RL, Pitts SH, Arikat H, et al (1994) Osteogenesis imperfecta type I: molecular heterogeneity for COL1A1 null alleles of type I collagen. *Am J Hum Genet* 55:638–647
- Zuppiroli A, Roman MJ, O'Grady M, Devereux RB (1998) A family study of anterior mitral leaflet thickness and mitral valve prolapse. *Am J Cardiol* 82:823–826